VKTX Stock — Viking Therapeutics Inc.: Cash, EV, Pipeline

Share price

$28.99

Market cap

$3,381.8M

Cash

$501.7M

Enterprise value

$2,880.1M

Balance sheet

Cash	$501.7M
Debt	$0.0M
Net cash	$501.7M
Enterprise value	$2,880.1M
Basic shares	116.7M shares
Fully diluted shares	130.7M shares
Fully diluted market cap	$3,788.9M
Cash per share	$4.30

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading VKTX daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Aug 12 - Sep 23	VK2735	Phase 3	Weight Loss	—
Aug 12 - Sep 23	VK2735	Phase 3	Weight Loss	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

VK2735

Phase 3 · Active

Target GLP-1/GIP receptors

Partnerships CordenPharma: multi-year manufacturing agreements (API + fill/finish for injectable and oral; prepayments 2026-2028).

Indications

Obesity (Phase 3)

Status note Dual GLP-1/GIP receptor agonist in oral and subcutaneous formulations. Subcutaneous: Phase 3 VANQUISH-1 (enrollment complete Nov 2025) and VANQUISH-2 (enrollment complete Mar 2026) ongoing. Oral: Phase 2 VENTURE-Oral data reported Aug 2025; exploratory maintenance dosing study enrollment complete Jan 2026.

VK3019

Phase 1 · Active

Target amylin/calcitonin receptors

Indications

Obesity (Phase 1)

Status note Novel amylin agonist from internally developed DACRA (dual amylin and calcitonin receptor agonist) program. IND filed Apr 2026; Phase 1 SAD initiated Jun 2026.

VK2809

Stage not disclosed · Active

Target thyroid hormone receptor beta (TRbeta)

Partnerships Ligand Pharmaceuticals: exclusive worldwide rights (Master License Agreement).

Indications

NASH/MASH (Stage not disclosed)

Status note Oral tissue/receptor-subtype selective TRbeta agonist. Phase 2b VOYAGE complete (52-week histology data Jun 2024); 8 completed clinical studies, 400+ subjects. No next-study plans stated in filing.

VK0214

Stage not disclosed · Active

Target thyroid hormone receptor beta (TRbeta)

Partnerships Ligand Pharmaceuticals: exclusive worldwide rights (Master License Agreement).

Indications

X-linked adrenoleukodystrophy (X-ALD) (Stage not disclosed)

Status note Oral TRbeta agonist for X-ALD. Phase 1b in AMN patients complete (Oct 2024). Company intends to pursue partnering/licensing before additional clinical studies.

VK5211

Stage not disclosed · Active

Target androgen receptor

Partnerships Ligand Pharmaceuticals: exclusive worldwide rights (Master License Agreement).

Indications

Muscle wasting / recovery from hip fracture surgery (Stage not disclosed)

Status note Oral non-steroidal selective androgen receptor modulator. Phase 2 proof-of-concept in hip fracture recovery reported Nov 2017. Company intends to pursue partnering/licensing before additional clinical studies.

Per-asset detail extracted from the 10-Q filed 2026-07-29. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	VK2735
Lead indication	Weight Loss
Lead phase	Phase 3
Active trials	2

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT07104383	Phase 3	Active, not recruiting	Sponsor	VKTX	—	Weight Loss	—
NCT07104500	Phase 3	Active, not recruiting	Sponsor	VKTX	—	Weight Loss	—

Sponsor-matched active trials from ClinicalTrials.gov (2 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 2 active trials for Viking Therapeutics, Inc. on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
ADAR1 Capital Management	574,038	+346,321	1.05%	2026-08-14
Ikarian Capital	9,717	no change	0.06%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

VKTX — Viking Therapeutics Inc.

Balance sheet

Price history

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Institutional holders